Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATEINT TREATMENT SUCCESS RATES
7 INDUSTRY INSIGHTS
7.1 PATENT ANALYSIS
7.2 DRUG TREATMENT RATE BY MATURED MARKETS
7.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
7.4 PATIENT FLOW DIAGRAM
7.5 KEY PRICING STRATEGIES
7.6 KEY PATIENT ENROLLMENT STRATEGIES
7.7 INTERVIEWS WITH HEMATOLOGISTS
7.8 INTERVIEWS WITH ONCOLOGISTS
7.9 INTERVIEWS WITH CANCER ORGANIZATIONS
7.1 OTHER KOL SNAPSHOTS
8 PIPELINE ANALYSIS
8.1 CLINICAL TRIALS AND PHASE ANALYSIS
8.2 DRUG THERAPY PIPELINE
8.3 PHASE III CANDIDATES
8.4 PHASE II CANDIDATES
8.5 PHASE I CANDIDATES
8.6 OTHERS (PRE-CLINICAL AND RESEARCH)
9 REGULATORY FRAMEWORK
10 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)
10.3 CLINICALLY ISOLATED SYNDROME (CIS)
10.4 PRIMARY PROGRESSIVE MS (PPMS)
10.5 SECONDARY PROGRESSIVE MS (SPMS)
11 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATIONS
11.2.1 DISEASE-MODIFYING DRUGS
11.2.1.1. MONOCLONAL ANTIBODY
11.2.1.1.1. MONOCLONAL ANTIBODY, BY TYPE
11.2.1.1.1.1 OCRELIZUMAB
11.2.1.1.1.2 NATALIZUMAB
11.2.1.1.1.3 DACLIZUMAB
11.2.1.1.1.4 OTHERS
11.2.1.1.2. MONOCLONAL ANTIBODY, BY DRUG TYPE
11.2.1.1.2.1 GENERIC
11.2.1.1.2.2 BRANDED
11.2.1.1.2.2.1. OCREVUS
11.2.1.1.2.2.2. TYSABRI
11.2.1.1.2.2.3. ZENAPAX
11.2.1.2. IMMUNOMODULATOR DRUGS
11.2.1.2.1. IMMUNOMODULATOR DRUGS, BY DRUG
11.2.1.2.1.1 GLATIRAMER
11.2.1.2.1.2 CLADRIBINE
11.2.1.2.1.3 TERIFLUNOMIDE
11.2.1.2.1.4 DIMETHYL FUMARATE
11.2.1.2.1.5 OTHERS
11.2.1.2.2. IMMUNOMODULATOR DRUGS, BY DRUG TYPE
11.2.1.2.2.1 GENERIC
11.2.1.2.2.2 BRANDED
11.2.1.2.2.2.1. GLATOPA
11.2.1.2.2.2.2. COPAXONE
11.2.1.2.2.2.3. MAVENCLAD
11.2.1.2.2.2.4. OTHERS
11.2.1.3. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS
11.2.1.3.1. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS, BY TYPE
11.2.1.3.1.1 PONESIMOD
11.2.1.3.1.2 FINGOLIMOD
11.2.1.3.1.3 SIPONIMOD
11.2.1.3.1.4 OZANIMOD
11.2.1.3.1.5 OTHERS
11.2.1.3.2. SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS, BY DRUG TYPE
11.2.1.3.2.1 GENERIC
11.2.1.3.2.2 BRANDED
11.2.1.3.2.2.1. PONVORY
11.2.1.3.2.2.2. ZEPOSIA
11.2.1.3.2.2.3. MAYZENT
11.2.1.3.2.2.4. ZEPOSIA
11.2.1.4. ANTI CANCER DRUGS
11.2.1.4.1. ANTI CANCER DRUGS, BY TYPE
11.2.1.4.1.1 MITOXANTRONE
11.2.1.4.1.2 CYCLOPHOSPHAMIDE
11.2.1.4.1.3 MELPHALAN FLUFENAMIDE
11.2.1.4.1.4 OTHERS
11.2.1.4.2. ANTI CANCER DRUGS, BY DRUG TYPE
11.2.1.4.2.1 GENERIC
11.2.1.4.2.2 BRANDED
11.2.1.4.2.2.1. PEPAXTO
11.2.1.4.2.2.2. CYTOXAN
11.2.1.4.2.2.3. NEOSAR
11.2.1.4.2.2.4. OTHERS
11.2.1.5. INTERFERONE
11.2.1.5.1. INTERFERONE, BY TYPE
11.2.1.5.1.1 INTERFERON BETA-1B
11.2.1.5.1.2 INTERFERON BETA-1A
11.2.1.5.1.3 PEGYLATED INTERFERON BETA-1A
11.2.1.5.1.4 OTHERS
11.2.1.5.2. INTERFERONE, BY DRUG TYPE
11.2.1.5.2.1 GENERIC
11.2.1.5.2.2 BRANDED
11.2.1.5.2.2.1. ROFERON
11.2.1.5.2.2.2. VIRAFERON
11.2.1.5.2.2.3. AVONEX
11.2.1.5.2.2.4. BETASERON
11.2.1.6. IMMUNOSUPPRESSANTS
11.2.1.6.1. IMMUNOSUPPRESSANTS, BY TYPE
11.2.1.6.1.1 AZATHIOPRINE
11.2.1.6.1.2 METHOTREXATE
11.2.1.6.1.3 OTHERS
11.2.1.6.2. IMMUNOSUPPRESSANTS, BY DRUG TYPE
11.2.1.6.2.1 AZASAN
11.2.1.6.2.2 IMURAN
11.2.1.6.2.3 REDITREX
11.2.1.6.2.4 TREXALL
11.2.1.6.2.5 XATMEP
11.2.2 SYMPTOMATIC THERAPIES
11.2.2.1. MUSCLE RELAXANTS
11.2.2.1.1. MUSCLE RELAXANTS, BY TYPE
11.2.2.1.1.1 BACLOFEN
11.2.2.1.1.2 TIZANIDINE
11.2.2.1.1.3 CYCLOBENZAPRINE
11.2.2.1.1.4 OTHERS
11.2.2.1.2. MUSCLE RELAXANTS, BY DRUG TYPE
11.2.2.1.2.1 GENERIC
11.2.2.1.2.2 BRANDED
11.2.2.1.2.2.1. LIORESAL
11.2.2.1.2.2.2. ZANAFLEX
11.2.2.1.2.2.3. FLEXERIL
11.2.2.2. FATIGUE MEDICATIONS
11.2.2.2.1. FATIGUE MEDICATIONS, BY TYPE
11.2.2.2.1.1 AMANTADINE
11.2.2.2.1.2 MODAFINIL
11.2.2.2.1.3 METHYLPHENIDATE
11.2.2.2.1.4 OTHERS
11.2.2.2.2. FATIGUE MEDICATIONS, BY DRUG TYPE
11.2.2.2.2.1 GENERIC
11.2.2.2.2.2 BRANDED
11.2.2.2.2.2.1. GOCOVRI
11.2.2.2.2.2.2. PROVIGIL
11.2.2.2.2.2.3. RITALIN
11.2.2.3. NEUROPATHIC PAIN
11.2.2.3.1. GABAPENTIN
11.2.2.3.2. CARBAMAZEPINE
11.2.2.3.3. AMITRIPTYLINE
11.2.2.3.4. OTHERS
11.2.2.4. CORTICOSTEROIDS
11.2.2.4.1. PREDNISONE
11.2.2.4.2. METHYLPREDNISOLONE
11.2.2.4.3. DEXAMETHASONE
11.2.2.4.4. PREDNISOLONE
11.2.2.4.5. BETAMETHASONE
11.2.2.4.6. OTHERS
11.3 PHYSIOTHERAPY
11.3.1 MANUAL THERAPY
11.3.2 SPECIALIZED TREATMENTS
11.3.3 JOINT MOBILIZATION TECHNIQUES
11.3.4 SUSPENSION THERAPY
11.3.5 RELAXATION TECHNIQUES
11.3.6 POSTURE CORRECTION METHODS
11.4 PLASMAPHERESIS
11.4.1 PLASMA EXCHANGE (PE)
11.4.2 DOUBLE-MEMBRANE-FILTRATION PLASMAPHERESIS (DFP)
11.4.3 ADSORPTION PLASMAPHERESIS
11.5 OTHERS
12 GLOBAL MULTIPLE SCLEROSIS MARKET , BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERIC
12.3 BRANDED
12.3.1 OCREVUS
12.3.2 TYSABRI
12.3.3 ZENAPAX
12.3.4 GLATOPA
12.3.5 COPAXONE
12.3.6 MAVENCLAD
12.3.7 PONVORY
12.3.8 ZEPOSIA
12.3.9 MAYZENT
12.3.10 ZEPOSIA
12.3.11 PEPAXTO
12.3.12 CYTOXAN
12.3.13 NEOSAR
12.3.14 ROFERON
12.3.15 VIRAFERON
12.3.16 AVONEX
12.3.17 BETASERON
12.3.18 BACLOFEN
12.3.19 TIZANIDINE
12.3.20 CYCLOBENZAPRINE
12.3.21 OTHERS
13 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLET
13.2.2 CAPSULE
13.2.3 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 OTHERS
14 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY PRESCRIPTION TYPE
14.1 OVERVIEW
14.2 OVER THE COUNTER
14.3 PRESCRIPTION
15 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY AGE GROUP
15.1 OVERVIEW
15.2 CHILDREN
15.3 ADULTS
15.4 GERIATRIC
16 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY GENDER
16.1 OVERVIEW
16.2 MALE
16.3 FEMALE
17 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 AMBULATORY SURGICAL CENTERS
17.6 OTHERS
18 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.3.1 ONLINE STORES
18.3.2 PHARMACY STORES
18.4 OTHERS
19 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY
EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1 EUROPE
19.1.1 GERMANY
19.1.2 U.K.
19.1.3 ITALY
19.1.4 FRANCE
19.1.5 SPAIN
19.1.6 RUSSIA
19.1.7 SWITZERLAND
19.1.8 TURKEY
19.1.9 BELGIUM
19.1.10 NETHERLANDS
19.1.11 DENMARK
19.1.12 SWEDEN
19.1.13 POLAND
19.1.14 NORWAY
19.1.15 FINLAND
19.1.16 REST OF EUROPE
20 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: EUROPE
20.5 MERGERS & ACQUISITIONS
20.6 NEW PRODUCT DEVELOPMENT & APPROVALS
20.7 EXPANSIONS
20.8 REGULATORY CHANGES
20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
21 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS
22 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY PROFILE
22.1 BIOGEN
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 TEVA NEUROSCIENCE, INC.
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 VIATRIS INC.
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 NOVARTIS AG
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 MERCK KGAA
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENTS
22.6 GLENMARK PHARMACEUTICALS LTD
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPMENTS
22.7 LUPIN
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPMENTS
22.8 CIPLA INC
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 SANOFI
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPMENTS
22.1 BAYER
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPMENTS
22.11 ABBVIE, INC
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 ABBOTT
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENTS
22.13 F. HOFFMANN-LA ROCHE LTD
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPMENTS
22.14 BRISTOL MYERS SQUIBB
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENTS
22.15 TG THERAPEUTICS, INC
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
5.3 EVOLUTION MS TREATMENT MARKET IN EUROPE LAST 10-20 YEARS
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 EUROPE CLINICAL TRIAL MARKET FOR MULTIPLE SCLEROSIS TREATMENT MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE MULTIPLE SCLEROSIS TREATMENT MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE MULTIPLE SCLEROSIS TREATMENT MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE MULTIPLE SCLEROSIS TREATMENT MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR MULTIPLE SCLEROSIS TREATMENT MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11 MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.1 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TYPE
15.1 OVERVIEW
15.2 CLINICALLY ISOLATED SYNDROME (CIS)
15.3 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)
15.4 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
15.5 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)
15.6 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)
16 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY THERAPEUTICS
16.1 OVERVIEW
16.2 APPROVED/ MARKETED MEDICATION
16.2.1 PREVENTIVE THERAPIES
16.2.1.1. ORAL MEDICATION
16.2.1.1.1. TECFIDERA
16.2.1.1.2. GILENYA
16.2.1.1.3. AUBAGIO
16.2.1.1.4. MAVENCLAD
16.2.1.1.5. MAYZENT
16.2.1.1.6. VUMERITY
16.2.1.1.7. OTHERS
16.2.1.2. INJECTABLE MEDICATION
16.2.1.2.1. INTERFERON BETA-1A
16.2.1.2.1.1 AVONEX
16.2.1.2.1.2 REBIF
16.2.1.2.1.3 OTHERS
16.2.1.2.2. GLATIRAMER ACETATE
16.2.1.2.2.1 COPAXONE
16.2.1.2.2.2 GLATOPA
16.2.1.2.2.3 OTHERS
16.2.1.2.3. INTERFERON BETA-1B
16.2.1.2.3.1 BETASERON
16.2.1.2.3.2 EXTAVIA
16.2.1.2.4. PLEGRIDY/PEGINTERFERON BETA-1A
16.2.1.2.5. CHEMOTHERAPY DRUG
16.2.1.2.6. MONOCLONAL ANTIBODIES
16.2.1.3. INFUSED MEDICATION
16.2.1.3.1. TYSABRI
16.2.1.3.2. OCREVUS
16.2.1.3.3. LEMTRADA
16.2.1.3.4. MITOXANTRONE
16.2.1.3.5. NOVANTRONE
16.2.1.3.6. OTHERS
16.2.1.4. HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
16.2.2 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS
16.2.2.1. CORTICOSTEROIDS
16.2.2.1.1. ORAL PREDNISONE
16.2.2.1.2. METHYLPREDNISOLONE
16.2.2.1.3. DEXAMETHASONE
16.2.2.1.4. PREDNISOLONE
16.2.2.1.5. BETAMETHASONE
16.2.2.1.6. OTHERS
16.2.2.2. BENZODIAZEPINES
16.2.2.2.1. CLONAZEPAM
16.2.2.2.2. DIAZEPAM
16.2.2.2.3. OTHERS
16.2.2.3. IMMUNOSUPPRESSANTS
16.2.2.3.1. AZATHIOPRINE
16.2.2.3.2. CYCLOPHOSPHAMIDE
16.2.2.3.3. METHOTREXATE
16.2.2.3.4. MITOXANTRONE
16.2.2.3.5. OTHERS
16.2.2.4. SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS
16.2.2.4.1. SIPONIMOD
16.2.2.4.2. FINGOLIMOD
16.2.2.4.3. OZANIMOD
16.2.2.4.4. OTHERS
16.2.2.5. DOPAMINE AGONISTS
16.2.2.5.1. OSMOLEX ER
16.2.2.5.2. GOCOVRI
16.2.2.5.3. OTHERS
16.2.2.6. NEUROMUSCULAR BLOCKERS
16.2.2.6.1. BOTOX
16.2.2.6.2. BOTOX COSMETIC
16.2.2.6.3. BOTULINUM TOXIN
16.2.2.7. ADRENOCORTICOTROPIC HORMONE
16.2.2.8. INTRAVENOUS IMMUNOGLOBULIN
16.2.2.9. PLASMAPHERESIS
16.2.2.10. OTHERS
16.2.3 SYMPTOMATIC THERAPIES
16.2.3.1. MUSCLE RELAXANTS
16.2.3.1.1. LIORESAL
16.2.3.1.2. ZANAFLEX
16.2.3.1.3. OTHERS
16.2.3.2. FATIGUE MEDICATIONS
16.2.3.2.1. GOCOVRI
16.2.3.2.2. OSMOLEX
16.2.3.2.3. PROVIGIL
16.2.3.2.4. RITALIN
16.2.3.2.5. OTHERS
16.2.3.3. STIMULANTS
16.2.3.3.1. MODAFINIL
16.2.3.3.2. ARMODAFINIL
16.2.3.3.3. OTHERS
16.2.3.4. ANTICONVULSANTS
16.2.3.4.1. GABAPENTIN
16.2.3.4.2. CARBAMAZEPINE
16.2.3.4.3. PREGABALIN
16.2.3.4.4. TOPIRAMATE
16.2.3.4.5. OTHERS
16.2.3.5. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
16.2.3.5.1. IBUPROFEN
16.2.3.5.2. NAPROXEN
16.2.3.5.3. DICLOFENAC
16.2.3.5.4. INDOMETHACIN
16.2.3.5.5. OTHERS
16.2.3.6. ANTIDIARRHEALS
16.2.3.7. POTASSIUM CHANNEL BLOCKERS
16.2.3.8. PHYSIOTHERAPY
16.2.3.9. LAXATIVES
16.2.3.10. OTHERS
16.3 PIPELINE DRUGS
16.3.1 SCM-0101
16.3.2 IMCY-MS-001
16.3.3 PIPE-307
16.3.4 ATA188
16.3.5 WP1303
16.3.6 FORALUMAB
16.3.7 OTHERS
17 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 TECFIDERA
17.2.2 GILENYA
17.2.3 AUBAGIO
17.2.4 AVONEX
17.2.5 TYSABRI
17.2.6 REBIF
17.2.7 COPAXONE
17.2.8 8 BETASERON
17.2.9 AMPYRA/FAMPYRA
17.2.10 OTHERS
17.3 GENERICS
18 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 TABLETS
18.2.2 CAPSULES
18.2.3 OTHERS
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 SUBCUTANEOUS
18.3.3 OTHERS
18.4 OTHERS
19 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY AGE GROUP
19.1 OVERVIEW
19.2 PEDIATRIC
19.2.1 MALE
19.2.2 FEMALE
19.3 ADULT
19.3.1 MALE
19.3.2 FEMALE
19.4 GERIATRIC
19.4.1 MALE
19.4.2 FEMALE
20 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET,BY GENDER
20.1 OVERVIEW
20.2 MALE
20.3 FEMALE
21 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.2.1 PUBLIC
21.2.1.1. TIER 1
21.2.1.2. TIER 2
21.2.1.3. TIER 3
21.2.2 PRIVATE
21.2.2.1. TIER 1
21.2.2.2. TIER 2
21.2.2.3. TIER 3
21.3 HOME HELATHCARE
21.4 SPECIALITY CENTRE
21.5 ACADEMIC AND RESEARCH INSTITUTES
21.6 OTHERS
22 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 DIRECT TENDERS
22.3 RETAIL SALES
22.3.1 ONLINE
22.3.1.1. E-STORES
22.3.1.2. COMPANY WEBSITE
22.3.1.3. OTHERS
22.3.2 OFFLINE
22.3.2.1. HOSPITAL PHARMACY
22.3.2.2. RETAIL PHARMACY
22.3.2.3. OTHERS
22.4 OTHERS
23 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: EUROPE
23.2 MERGERS & ACQUISITIONS
23.3 NEW PRODUCT DEVELOPMENT & APPROVALS
23.4 EXPANSIONS
23.5 REGULATORY CHANGES
23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS
25 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY
EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 EUROPE
25.1.1 GERMANY
25.1.2 FRANCE
25.1.3 U.K.
25.1.4 ITALY
25.1.5 SPAIN
25.1.6 RUSSIA
25.1.7 TURKEY
25.1.8 BELGIUM
25.1.9 DENMARK
25.1.10 NETHERLANDS
25.1.11 SWITZERLAND
25.1.12 SWEDEN
25.1.13 POLAND
25.1.14 NORWAY
25.1.15 FINLAND
25.1.16 REST OF EUROPE
25.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY PROFILE
26.1 MARKETED /APPROVED MANUFRACTURES
26.1.1 BIOGEN
26.1.1.1. COMPANY OVERVIEW
26.1.1.2. REVENUE ANALYSIS
26.1.1.3. GEOGRAPHIC PRESENCE
26.1.1.4. PRODUCT PORTFOLIO
26.1.1.5. RECENT DEVELOPMENTS
26.1.2 NOVARTIS AG
26.1.2.1. COMPANY OVERVIEW
26.1.2.2. REVENUE ANALYSIS
26.1.2.3. GEOGRAPHIC PRESENCE
26.1.2.4. PRODUCT PORTFOLIO
26.1.2.5. RECENT DEVELOPMENTS
26.1.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)
26.1.3.1. COMPANY OVERVIEW
26.1.3.2. REVENUE ANALYSIS
26.1.3.3. GEOGRAPHIC PRESENCE
26.1.3.4. PRODUCT PORTFOLIO
26.1.3.5. RECENT DEVELOPMENTS
26.1.4 MERCK KGAA
26.1.4.1. COMPANY OVERVIEW
26.1.4.2. REVENUE ANALYSIS
26.1.4.3. GEOGRAPHIC PRESENCE
26.1.4.4. PRODUCT PORTFOLIO
26.1.4.5. RECENT DEVELOPMENTS
26.1.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
26.1.5.1. COMPANY OVERVIEW
26.1.5.2. REVENUE ANALYSIS
26.1.5.3. GEOGRAPHIC PRESENCE
26.1.5.4. PRODUCT PORTFOLIO
26.1.5.5. RECENT DEVELOPMENTS
26.1.6 F. HOFFMANN-LA ROCHE LTD
26.1.6.1. COMPANY OVERVIEW
26.1.6.2. REVENUE ANALYSIS
26.1.6.3. GEOGRAPHIC PRESENCE
26.1.6.4. PRODUCT PORTFOLIO
26.1.6.5. RECENT DEVELOPMENTS
26.1.7 ACORDA THERAPEUTICS, INC
26.1.7.1. COMPANY OVERVIEW
26.1.7.2. REVENUE ANALYSIS
26.1.7.3. GEOGRAPHIC PRESENCE
26.1.7.4. PRODUCT PORTFOLIO
26.1.7.5. RECENT DEVELOPMENTS
26.1.8 AMNEAL PHARMACEUTICALS LLC
26.1.8.1. COMPANY OVERVIEW
26.1.8.2. REVENUE ANALYSIS
26.1.8.3. GEOGRAPHIC PRESENCE
26.1.8.4. PRODUCT PORTFOLIO
26.1.8.5. RECENT DEVELOPMENTS
26.1.9 BAYER AG
26.1.9.1. COMPANY OVERVIEW
26.1.9.2. REVENUE ANALYSIS
26.1.9.3. GEOGRAPHIC PRESENCE
26.1.9.4. PRODUCT PORTFOLIO
26.1.9.5. RECENT DEVELOPMENTS
26.1.10 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)
26.1.10.1. COMPANY OVERVIEW
26.1.10.2. REVENUE ANALYSIS
26.1.10.3. GEOGRAPHIC PRESENCE
26.1.10.4. PRODUCT PORTFOLIO
26.1.10.5. RECENT DEVELOPMENTS
26.1.11 HIKMA PHARMACEUTICALS PLC
26.1.11.1. COMPANY OVERVIEW
26.1.11.2. REVENUE ANALYSIS
26.1.11.3. GEOGRAPHIC PRESENCE
26.1.11.4. PRODUCT PORTFOLIO
26.1.11.5. RECENT DEVELOPMENTS
26.1.12 MALLINCKRODT PHARMACEUTICALS
26.1.12.1. COMPANY OVERVIEW
26.1.12.2. REVENUE ANALYSIS
26.1.12.3. GEOGRAPHIC PRESENCE
26.1.12.4. PRODUCT PORTFOLIO
26.1.12.5. RECENT DEVELOPMENTS
26.1.13 VITARIS INC.
26.1.13.1. COMPANY OVERVIEW
26.1.13.2. REVENUE ANALYSIS
26.1.13.3. GEOGRAPHIC PRESENCE
26.1.13.4. PRODUCT PORTFOLIO
26.1.13.5. RECENT DEVELOPMENTS
26.1.14 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)
26.1.14.1. COMPANY OVERVIEW
26.1.14.2. REVENUE ANALYSIS
26.1.14.3. GEOGRAPHIC PRESENCE
26.1.14.4. PRODUCT PORTFOLIO
26.1.14.5. RECENT DEVELOPMENTS
26.1.15 PFIZER INC.
26.1.15.1. COMPANY OVERVIEW
26.1.15.2. REVENUE ANALYSIS
26.1.15.3. GEOGRAPHIC PRESENCE
26.1.15.4. PRODUCT PORTFOLIO
26.1.15.5. RECENT DEVELOPMENTS
26.1.16 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
26.1.16.1. COMPANY OVERVIEW
26.1.16.2. REVENUE ANALYSIS
26.1.16.3. GEOGRAPHIC PRESENCE
26.1.16.4. PRODUCT PORTFOLIO
26.1.16.5. RECENT DEVELOPMENTS
26.1.17 JOHNSON & JOHNSON CONSUMER INC.
26.1.17.1. COMPANY OVERVIEW
26.1.17.2. PRODUCT PORTFOLIO
26.1.17.3. REVENUE ANALYSIS
26.1.17.4. GEOGRAPHIC PRESENCE
26.1.17.5. PRODUCT PORTFOLIO
26.1.18 PERRIGO COMPANY PLC,
26.1.18.1. COMPANY OVERVIEW
26.1.18.2. PRODUCT PORTFOLIO
26.1.18.3. REVENUE ANALYSIS
26.1.18.4. GEOGRAPHIC PRESENCE
26.1.18.5. PRODUCT PORTFOLIO
26.1.19 GLENMARK PHARMACEUTICAL INC., USA
26.1.19.1. COMPANY OVERVIEW
26.1.19.2. REVENUE ANALYSIS
26.1.19.3. GEOGRAPHIC PRESENCE
26.1.19.4. PRODUCT PORTFOLIO
26.1.19.5. RECENT DEVELOPMENTS
26.1.20 GLAXOSMITHKLINE PLC.
26.1.20.1. COMPANY OVERVIEW
26.1.20.2. PRODUCT PORTFOLIO
26.1.20.3. REVENUE ANALYSIS
26.1.20.4. GEOGRAPHIC PRESENCE
26.1.20.5. PRODUCT PORTFOLIO
26.2 PIPELINE COMPANIES
26.2.1 IMCYSE
26.2.1.1. COMPANY OVERVIEW
26.2.1.2. PRODUCT PORTFOLIO
26.2.1.3. REVENUE ANALYSIS
26.2.1.4. GEOGRAPHIC PRESENCE
26.2.1.5. PRODUCT PORTFOLIO
26.2.2 WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.
26.2.2.1. COMPANY OVERVIEW
26.2.2.2. PRODUCT PORTFOLIO
26.2.2.3. REVENUE ANALYSIS
26.2.2.4. GEOGRAPHIC PRESENCE
26.2.2.5. PRODUCT PORTFOLIO
26.2.3 TIZIANA LIFE SCIENCES
26.2.3.1. COMPANY OVERVIEW
26.2.3.2. PRODUCT PORTFOLIO
26.2.3.3. REVENUE ANALYSIS
26.2.3.4. GEOGRAPHIC PRESENCE
26.2.3.5. PRODUCT PORTFOLIO
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
